Presentation is loading. Please wait.

Presentation is loading. Please wait.

Protein Engineering for Cross-platform Applicability in Biopharmaceutical R&D Dale Athey, CEO.

Similar presentations


Presentation on theme: "Protein Engineering for Cross-platform Applicability in Biopharmaceutical R&D Dale Athey, CEO."— Presentation transcript:

1 Protein Engineering for Cross-platform Applicability in Biopharmaceutical R&D Dale Athey, CEO

2 A growing share of all medicines produced are biologics “ “ The biologics market

3 Better tools are required across the biopharmaceutical manufacturing chain Preclinical & clinical developmentCommercial manufacturing Pre-IND Phase 1 Phase 2 Phase 3 Approved Biopharmaceutical 5-8 yrs20 yrs “ “

4 Immobilisation of polypeptide target molecules is critical for most analytical tools and separations “ “ Chromatography columns Analytical instruments 96 well-plate Sources: Bio-rad chromatography column ForteBio Octet Thermo Scientific Nunc

5 Methods often rely on adsorption or chemical coupling directly to a surface  Poor functionality  Lack of orientation  Denaturation  Inaccessible active sites  Poor reproducibility  Often expensive  Difficult scale-up “ “

6 Bespoke affinity ligand molecules that can be incorporated across platforms and across the biopharma manufacturing value chain  Close to 100% of function  Precise orientation  Structurally intact  Active sites accessible by design  Excellent reproducibility  Cost-effective solution  Scalability “ “

7 Control your success - through full control over your protein surface Target protein / peptide Orla’s SBU Produced as single protein Surface OrlaSURF “ “  Simple  Self-immobilising  Flexible  Robust, stable  Reproducible

8 Protein engineering for improved biopharma tools ScFv selection Antigen selection Non-Ab therapeutic protein, cell Therapeutic antibody OrlaSURF fusion Assay plates, beads etc Analytical platforms Chromatography resins “ “

9 Better tools are required across the biopharmaceutical manufacturing chain Preclinical & clinical developmentCommercial manufacturing 5-8 yrs20 yrs “ “ available Pre-IND Phase 1 Phase 2 Phase 3 Approved Biopharmaceutical Improve your products and processes through higher accuracy and improved efficiency OrlaSURF throughout the process

10 Better tools are required across the biopharmaceutical manufacturing chain “ “ available www.orlaproteins.com enquiries@orlaproteins.com +44 191 231 3127


Download ppt "Protein Engineering for Cross-platform Applicability in Biopharmaceutical R&D Dale Athey, CEO."

Similar presentations


Ads by Google